Search results
Results from the WOW.Com Content Network
The Self-administered Gerocognitive Examination is a brief cognitive assessment instrument for mild cognitive impairment (MCI) and early dementia, created by Douglas Scharre, Professor of Clinical Neurology and Psychiatry at Ohio State University Wexner Medical Center in Columbus, Ohio. A digital version exists. [1]
A recently conducted study in Australia [8] found that the GPCOG in comparison to the MMSE and Rowland Universal Dementia Assessment Scale (RUDAS) [9] was best to rule out dementia in a multicultural cohort of 151 community-dwelling persons. [8] Its sensitivity was higher (98.1) as compared to MMSE and RUDAS (84.3 and 87.7, respectively).
[1] [2] It is commonly used in medicine and allied health to screen for dementia. It is also used to estimate the severity and progression of cognitive impairment and to follow the course of cognitive changes in an individual over time; thus making it an effective way to document an individual's response to treatment.
Pre-dementia or early-stage dementia (stages 1, 2, and 3). In this initial phase, a person can still live independently and may not exhibit obvious memory loss or have any difficulty completing ...
At the recommended cut-off scores of 88 and 83, the ACE was reported to have good sensitivity and specificity for identifying different forms of dementia and other impairments of memory and judgement (0.93 and 0.71; 0.82 and 0.96, respectively). [5] The ACE also incorporated the MMSE, such that this score (out of 30) might also be generated. [2 ...
Therefore, early and accurate diagnosis of dementia and staging can be essential to proper clinical care. Without the ability to reliably assess dementia across the board, the misuse of anti-dementia compounds could have negative consequences, such as patients receiving the wrong medication, or not receiving treatment in the early stages of ...
Frontotemporal dementia (FTD) is an early onset disorder that mostly occurs between the ages of 45 and 65, [13] but can begin earlier, and in 20–25% of cases onset is later. [11] [14] Men and women appear to be equally affected. [15] It is the most common early presenting dementia. [16]
A study in 2007 looked at how reminiscence therapy affected both cognitive and affective function in 102 demented elderly. The study used established scales to determine the effect of reminiscence treatment using a pre- and post-test self-report design. For cognitive function, the study used the Mini-Mental State Examination (MMSE).